麝香通心滴丸联合氯吡格雷治疗冠心病心绞痛的临床研究
|
摘要
目的研究麝香通心滴丸联合硫酸氢氯吡格雷片治疗冠心病心绞痛的临床疗效。方法选取2015年9月—2018年9月上海市第一人民医院宝山分院收治的124例冠心病心绞痛患者作为研究对象,将患者随机分为对照组和治疗组,每组各62例。对照组患者口服硫酸氢氯吡格雷片,75 mg/次,1次/d;治疗组在对照组治疗的基础上口服麝香通心滴丸,2丸/次,3次/d。两组患者均治疗4周。观察两组患者的临床疗效和心电图疗效,比较两组治疗前后的临床症状缓解情况和血液流变学指标。结果治疗后,对照组和治疗组的总有效率分别为83.87%、95.16%,两组比较差异具有统计学意义(P<0.05)。治疗后,对照组和治疗组的心电图总有效率分别为82.26%、93.55%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者心绞痛发作次数和持续时间显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组心绞痛发作次数和持续时间显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组的全血黏度(WBV)、血浆黏度(PV)、纤维蛋白原(FIB)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组血液流变学指标显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论麝香通心滴丸联合硫酸氢氯吡格雷片治疗冠心病心绞痛具有较好的临床疗效,能显著缓解临床症状,改善血液流变学,且安全性较高,具有一定的临床推广应用价值。
Objective To study the clinical efficacy of Shexiang Tongxin Dropping Pills combined with Clopidogrel Bisulfate Tablets in treatment of coronary heart disease with angina pectoris. Methods Patients(124 cases) with coronary heart disease with angina pectoris in Baoshan Branch of Shanghai First People's Hospital from September 2015 to September 2018 were randomly divided into control and treatment groups, and each group had 62 cases. Patients in the control group were po administered with Clopidogrel Bisulfate Tablets, 75 mg/time, once daily. Patients in the treatment group were po administered with Shexiang Tongxin Dropping Pills on the basis of the control group, 2 pills/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy and electrocardiogram efficacy were evaluated, and the clinical symptom remission and hemorheological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 83.87% and 95.16%, respectively, and there were differences between two groups(P < 0.05). After treatment, the efficacy of electrocardiogram in the control and treatment groups were 82.26% and 93.55%, respectively, and there was difference between two groups(P < 0.05). After treatment, the angina attack frequency and duration in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the angina attack frequency and duration in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05).After treatment, the levels of WBV, PV, and FIB in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, hemorheological indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Shexiang Tongxin Dropping Pills combined with Clopidogrel Bisulfate Tablets has a good effect in treatment of coronary heart disease with angina pectoris, can alleviate clinical symptoms, improve hemorheology, with high safety, which has a certain clinical application value.
Objective To study the clinical efficacy of Shexiang Tongxin Dropping Pills combined with Clopidogrel Bisulfate Tablets in treatment of coronary heart disease with angina pectoris. Methods Patients(124 cases) with coronary heart disease with angina pectoris in Baoshan Branch of Shanghai First People's Hospital from September 2015 to September 2018 were randomly divided into control and treatment groups, and each group had 62 cases. Patients in the control group were po administered with Clopidogrel Bisulfate Tablets, 75 mg/time, once daily. Patients in the treatment group were po administered with Shexiang Tongxin Dropping Pills on the basis of the control group, 2 pills/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy and electrocardiogram efficacy were evaluated, and the clinical symptom remission and hemorheological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 83.87% and 95.16%, respectively, and there were differences between two groups(P < 0.05). After treatment, the efficacy of electrocardiogram in the control and treatment groups were 82.26% and 93.55%, respectively, and there was difference between two groups(P < 0.05). After treatment, the angina attack frequency and duration in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the angina attack frequency and duration in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05).After treatment, the levels of WBV, PV, and FIB in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, hemorheological indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Shexiang Tongxin Dropping Pills combined with Clopidogrel Bisulfate Tablets has a good effect in treatment of coronary heart disease with angina pectoris, can alleviate clinical symptoms, improve hemorheology, with high safety, which has a certain clinical application value.
引文
[1]李延辉.慢性稳定性冠心病诊治进展—诊断和危险分层[J].人民军医, 2007, 50(11):668-669.
[2]闫洁,袁森.银杏蜜环口服溶液联合阿司匹林肠溶片和氯吡格雷治疗冠心病心绞痛的疗效观察[J].现代药物与临床, 2016, 31(10):1575-1578.
[3]庄晓华,傅咏华,凌佳,等.麝香通心滴丸联合美托洛尔治疗冠心病心绞痛的疗效观察[J].现代药物与临床, 2018, 33(5):1052-1055.
[4]陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社, 2008:274.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:72-73.
[6]薛树仁.冠状动脉微循环及微血管性心绞痛的研究进展[J].中国动脉硬化杂志, 2006, 14(2):182-184.
[7]吴静,陈嘉龙,燕成英,等.氯吡格雷对冠心病合并糖尿病患者行冠脉介入治疗后YKL-40、NF-κB的影响[J].药物评价研究, 2017, 40(9):1310-1314.
[8]李文华,吴晓军,李桂新,等.麝香通心滴丸治疗冠心病心绞痛的系统评价[J].西北国防医学杂志,2018,39(5):281-284.
[9]安巍,王红红,张巧令.冠心病心绞痛治疗前后血液流变学变化及临床意义[J].山西医药杂志,1999,28(6):474-475.
[2]闫洁,袁森.银杏蜜环口服溶液联合阿司匹林肠溶片和氯吡格雷治疗冠心病心绞痛的疗效观察[J].现代药物与临床, 2016, 31(10):1575-1578.
[3]庄晓华,傅咏华,凌佳,等.麝香通心滴丸联合美托洛尔治疗冠心病心绞痛的疗效观察[J].现代药物与临床, 2018, 33(5):1052-1055.
[4]陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社, 2008:274.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:72-73.
[6]薛树仁.冠状动脉微循环及微血管性心绞痛的研究进展[J].中国动脉硬化杂志, 2006, 14(2):182-184.
[7]吴静,陈嘉龙,燕成英,等.氯吡格雷对冠心病合并糖尿病患者行冠脉介入治疗后YKL-40、NF-κB的影响[J].药物评价研究, 2017, 40(9):1310-1314.
[8]李文华,吴晓军,李桂新,等.麝香通心滴丸治疗冠心病心绞痛的系统评价[J].西北国防医学杂志,2018,39(5):281-284.
[9]安巍,王红红,张巧令.冠心病心绞痛治疗前后血液流变学变化及临床意义[J].山西医药杂志,1999,28(6):474-475.